Andrea S. Blevins Primeau, PhD, MBA

High-dose chemotherapy plus transplant improved outcomes compared with chemoimmunotherapy in a phase 3 trial of patients with primary CNS lymphoma.

Researchers sought to determine whether uMRD could determine discontinuation of venetoclax or the addition of ibrutinib in patients with R/R CLL.

Black cancer patients are less likely than their White counterparts to receive shorter radiotherapy regimens, a study suggests.

Some patients do not understand common phrases oncologists use, such as “your tumor is progressing” or “your nodes are positive.”

Zanubrutinib may produce superior outcomes to ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Performing liquid biopsy before tissue biopsy reveals more biomarkers in patients with non-small cell lung cancer, a study suggests.

Cell-free DNA fragmentome analysis can be used to detect hepatocellular carcinoma, according to researchers.

Using ctDNA testing to predict recurrence and guide therapy in triple-negative breast cancer is challenging, according to researchers.

More than one-third of patients with non-small cell lung cancer treated upfront with nivolumab plus ipilimumab were alive at 3 years.

Lenalidomide increases the risk of developing a second primary malignancy in patients with multiple myeloma, a meta-analysis suggests.